73 results about "Antidepressant" patented technology

Dosage forms, drug delivery systems, and methods related to dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Provided herein are, inter alia, methods for identifying subjects suffering from depression that will respond to treatment with an antidepressant.

The invention relates to an antidepressant pharmaceutical composition and application thereof, and particularly discloses a pharmaceutical composition for treating depression as well as a preparation method and application thereof. The active pharmaceutical ingredients of the pharmaceutical composition are prepared from the following traditional Chinese medicines in parts by weight: 500 to 600 parts of radix bupleuri, 500 to 600 parts of fructus aurantii immaturus, 500 to 600 parts of radix aucklandiae, 500 to 600 parts of pericarpium citri reticulatae, 500 to 600 parts of rhizoma pinelliae preparata, 750 to 900 parts of herba taraxaci, 500 to 600 parts of scorched fructus crataegi, 300 to 360 parts of scorched semen arecae, 500 to 600 parts of paederia scandens, 300 to 400 parts of radix codonopsis, 300 to 400 parts of rhizoma corydalis and 500 to 600 parts of fried medicated leaven. The pharmaceutical composition has a remarkable curative effect on depression, animal experiments show that the pharmaceutical composition can remarkably enhance the social coefficient (showing that the pharmaceutical composition can improve social fear of depression patients) and improve sweet water preference (showing that the pharmaceutical composition is beneficial to transformation of negative emotions such as interest deficiency of the depression patients), and the pharmaceutical composition is safe to take, free of adverse reaction and toxic and side effects and free of toxic and side effects. And the composition can take effect quickly, and can take effect generally within 1-2 weeks after medication.

Provided herein are, inter alia, methods for identifying subjects suffering from depression that will respond to treatment with an antidepressant.

The invention relates to the field of medicines, in particular to a crystal form A and a crystal form B of 20 (S)-protopanoxadiol as well as a preparation method and application of the crystal form A and the crystal form B. The crystal form A and the crystal form B provided by the invention are different from the existing known 20 (S)-protopanoxadiol crystal form, have distinct contours, can be perfectly reproduced, and have good characteristics in bulk density, fluidity and stability and in treatment of diseases such as depression resistance, anxiety resistance, cognitive disorder resistance, tumor resistance or cardiovascular resistance; the method has a wide application prospect in drug development of 20 (S)-protopanoxadiol.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an adenosine A2a / A2b receptor dual antagonist in preparation of an anti-depression medicine and a medicine for preventing or treating depression. The invention provides a new application of the adenosine A2aR / A2bR double antagonist, animal experiments prove that the adenosine A2aR / A2bR double antagonist AB928 can effectively treat depression of mice, does not have obvious toxic or side effects, increases indications of the AB928, and has a prospect of being applied as an anti-depression drug in practice, so that the medical application of the adenosine A2aR / A2bR double antagonist AB928 is further expanded.

Dosage forms, drug delivery systems, and methods related to dextromethorphan or improved therapeutic effects are disclosed. Typically, an antidepressant, such as bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

The present invention relates to a novel Noradrenergic and Specific Serotonergic Anxiolytic and Antidepressant (NaSSA) and a method for the production and use thereof for treating mental disorders.The subject of this invention is a novel noradrenergic and specific serotonergic drug for the treatment of mental disorders in humans, which is 2,8-dimethyl-5-(2-phenylethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole hydrochloride (A·HCl), a polymorphous modification thereof, and methods for the production and use thereof.

The invention discloses a lactobacillus paracasei MLL28 strain and application thereof in resisting depression and inflammation, and belongs to the technical field of biomedicine. The strain is preserved in the China General Microbiological Culture Collection Center, called CGMCC for short, the preservation address is Institute of Microbiology, Chinese Academy of Sciences, No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing, the preservation number is CGMCC No.37583, the preservation date is January 30, 2026, and the taxonomic name is Lactobacillus paracasei. The strain provided by the invention has good tolerance to gastrointestinal tract environment, can significantly improve depression-like behaviors and regulate the levels of neurotrophic factors, neurotransmitters and inflammation-related factors, has good anti-depression and anti-inflammatory effects, and can provide a new technical approach for emotion regulation, depression state improvement and anti-inflammation.

The present disclosure generally relates to the surprising discovery that azabicyclothiophenyl compounds are capable of treating depression in subjects resistant to antidepressant treatment and / or treating depression-related cognitive impairment in subjects resistant to antidepressant treatment.

The invention relates to the technical field of biomedicine and pharmacy, and discloses application of polypeptide in preparation of a medicine for treating and / or preventing depression. An IL-33 / ST2 signal channel in an LS brain region is a key endogenous protection mechanism for maintaining normal emotion, and by constructing a CSDS depression mouse model for verification, the 81st-95th amino acid sequence of the IL-33 protein is determined to be a core active fragment of the IL-33 protein combined with an ST2 receptor and exerting an anti-depression function. Experiments prove that no matter through intraperitoneal injection or LS brain region local injection, the polypeptide can significantly improve mouse depression-like behaviors induced by a CSDS or LPS model. The polypeptide provided by the invention is small in molecular weight, can pass through a blood brain barrier after being fused with TAT, and provides important candidate molecules and treatment strategies for developing novel and effective antidepressant drugs.

The invention relates to a composition comprising a piperazine-benzazepine, a buffer and a surfactant, and uses of such compositions such as treating, preventing, and / or suppressing symptoms of schizophrenia, schizoaffective disorders, and / or Parkinson's disease. The compositions have improved parameters such as a lower variance in pH, improved stability during storage, and lower solubility of piperazine-benzazepines, resulting in piperazine-benzazepine particle formation with improved particle size and particle size distribution. The compositions are useful as therapeutic agent, for instance through parenteral administration to a subject.

The application belongs to the technical field of medicines, and specifically discloses an anti-depression m-hydroxybenzoic acid compound and a preparation method and application thereof; the m-hydroxybenzoic acid compound Hyperioxides A-F provided by the application has not been reported; the six compounds have good anti-depression effects, and further research shows that the compounds Hyperioxide A, Hyperioxide D, Hyperioxide E and Hyperioxide F have significant protective effects on SH-SY5Y cells induced by corticosterone, and are superior to positive drugs fluoxetine and Luoyoutei, and can be used for developing drugs for treating depression.

The invention relates to (i) the prevention or treatment of a sleep disturbance, preferably in a patient having neuropathic pain; and / or (ii) the prevention or treatment of neuropathic pain in a patient having a sleep disturbance; and / or (iii) the prevention or treatment of neuropathic pain in a patient having been treated previously and / or being treated concomitantly with an analgesic medication for relief of neuropathic pain, preferably selected from antiepileptics, antidepressants and opioid analgesics, wherein the patient preferably has a sleep disturbance; in either cases by means of one or more high-concentration capsaicin and / or capsaicinoid topical dose units, preferably pharmaceutical patches, comprising capsaicin and / or capsaicinoid at a concentration of at least 2.5 wt.-%, relative to the total weight of dose unit.

The application discloses an IGFBP-2 derived polypeptide and application thereof in preparation of an antidepressant, and relates to the technical field of biological medicines. The amino acid sequence of the polypeptide is Pro-Lys-Lys-Leu-Arg-Pro, the N terminal of which is acetylated and the C terminal of which is amidated, and the amino acid sequence is shown as SEQ ID NO:1. The polypeptide has a small molecular weight, can easily penetrate the blood-brain barrier, and has good stability after terminal modification. Animal experiments prove that the polypeptide can significantly improve the depressive behavior of Shank3 gene knockout mice, including improving the spatial cognitive ability, enhancing the social interaction and curiosity, and relieving the anxiety behavior. Cell experiments prove that the polypeptide can significantly improve the viability of hippocampal neuron cells from Shank3 gene knockout mice, and up-regulate the expression level of synaptic plasticity related proteins GluA1 and SYN1. The polypeptide can be prepared by a chemical synthesis method, has low cost, and can be used for preparing a medicine for preventing or treating depression (especially depression related to Shank3 gene mutation).

The invention relates to the technical field of neurasthenia, in particular to a pharmaceutical composition as well as a preparation method and application thereof. The pharmaceutical composition is prepared from various glycoside substances and the like as raw materials. The pharmaceutical composition has the effects of treating or preventing ways beneficial to improving corresponding symptoms of neurasthenia of patients, such as nerve headache, headache caused by hysteria and the like. By intervening and activating an ERK-CREB signal channel, the composition is beneficial for inhibiting neurasthenia and enhancing the neuroprotective effect, and plays a positive role in resisting depression.

The present application relates to the field of biological science, and particularly relates to the use of a SCN11A protein detection reagent in the preparation of a depression screening and depression treatment effect evaluation kit. It is found for the first time that the expression level of SCN11A protein in the peripheral blood serum of a depression patient is significantly higher than that of a healthy subject. The reagent for detecting SCN11A protein is used in the preparation of a depression screening kit, so that effective screening of depression and evaluation of the treatment effect of depression can be realized.

The invention relates to the technical field of medicines, and particularly provides application of a 6-(substituted pyridine-4-yl)-5-(substituted phenyl)-1, 2, 4-triazine compound derivative in preparation of an antidepressant drug. A cell experiment proves that the 6-(substituted pyridine-4-yl)-5-(substituted phenyl)-1, 2, 4-triazine compound is an antagonist of an adenosine 2A receptor, and a plurality of animal model experiments prove that the 6-(substituted pyridine-4-yl)-5-(substituted phenyl)-1, 2, 4-triazine compound has a relatively good treatment effect on a plurality of depression models. The compound has an application prospect of being used as an anti-depression treatment drug.

The invention belongs to the technical field of medicines, and particularly discloses a novel tricyclic alpha acid compound as well as a preparation method and application thereof. According to the present invention, the novel tricyclic alpha acid compounds (+ / -)-Humulunes M-O and (-)-Garcinielliptone HE have not been reported at present; the compound has a remarkable protection effect on HT22 cells induced by corticosterone and SH-SY5Y cells induced by LPS (Lipopolysaccharide), and can be used for developing medicines for treating depression.

The present invention relates to the field of pharmacy, and in particular to compounds of formula (I) as pharmaceutically active compounds. Compounds of formula (I) have been proven for the first time to be particularly useful for the treatment of depression and eating disorders related to depression, or diseases with depressive pathology as well as for the treatment of appetite related side effects of antidepressants and antipsychotics.

Disclosed are a benzothiazepine compound, a preparation method therefor, and use thereof. Specifically disclosed is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound or the salt thereof has one or more of the following advantages: selective inhibition of HDAC6, stable metabolism, low toxicity, inhibition of tumor cells, protection of nerve cells, and having a relatively good in vivo antidepressant effect, and is expected to be used as a novel therapeutic agent for the clinical treatment of cancer or diseases of the nervous system.

The invention discloses a benzodihydrofuran tri-fused ring compound as well as a pharmaceutical composition and application of the benzodihydrofuran tri-fused ring compound. Specifically, the invention provides a compound shown as a formula I or pharmaceutically acceptable salt thereof. The compound disclosed by the invention has a good effect on a 5-HT2A receptor, has an effect of treating mental diseases, and particularly has a relatively good effect on resisting depression. # imgabs0 #

The present invention relates to 5-MeO-DMT or a pharmaceutically acceptable salt thereof for use in treating a patient who has been diagnosed with a mental disorder or a nervous system disorder by administration of a 5-MeO-DMT / salt treatment course. The 5-MeO-DMT / salt treatment course involves administration of one or more doses of 5-MeO-DMT or a pharmaceutically acceptable salt thereof on a single day to remove or alleviate one or more symptoms of the mental disorder or the nervous system disorder. The patient is also treated with one or more antidepressant(s).

The present invention relates to the field of biotechnology, and specifically discloses a tsRNA biomarker, a kit and an application thereof for diagnosing depression. The marker includes a tsRNA numbered tiRNA-Gly-GCC-001; the number is the number of RNA in the MINTbase database, and the nucleotide sequence of the tiRNA-Gly-GCC-001 is shown in SQEIDNO.1 in the sequence table. The present invention uses tsRNA as a biomarker for diagnosing depression and a biomarker for predicting the efficacy of antidepressant drugs, which has high stability, good specificity and sensitivity, and high diagnostic reference value.

Provided herein are, inter alia, methods for identifying subjects suffering from depression that will respond to treatment with an antidepressant.

The present invention discloses a strain of Lactobacillus johnsonii for relieving anxiety and anti-depression and its postbiotics and applications, belonging to the field of microbial fermentation technology. The present invention screens and obtains a strain of Lactobacillus johnsonii, obtains the bacterial body and its postbiotics by culture, and forms a complex with a dandelion extract. The complex exhibits a synergistic effect, which is specifically manifested in that the number of times mice enter the open arm in the elevated plus maze experiment increases, the residence time is prolonged, and higher curiosity and better anxiety relief ability are exhibited; in the tail suspension experiment, the immobility time of mice is reduced, showing a higher desire to escape and anti-depression ability. The present invention is not only of practical value for the comprehensive utilization of Lactobacillus johnsonii and its postbiotics, but also of important value for the body in relieving anxiety and anti-depression.

The invention discloses application of nomilin in preparation of a medicine for treating and preventing depression, nomilin has a remarkable treatment effect on mouse depression-like behaviors induced by LPS (lipopolysaccharide), and nomilin can increase expression of PSD-95, SNAP-25 and Synaptophysin synaptic proteins so as to promote recovery of depression nerve synaptic structures and functions. The effects of resisting depression and resisting Alzheimer's disease are achieved.

A system for remotely determining the potential presence of depression in a user. The system includes a virtual agent that administers one or more tasks to the user. The user performs the tasks and the performance is captured by a camera. The captured audiovisual data is sent to a server that derives objective metrics which are then applied to a classifying algorithm. If certain metrics meet certain thresholds, the system determines that the user is exhibiting depression symptoms. In embodiments, the system can further determine whether a user has been taking depression medication.